相关实验视频
Updated: Sep 18, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
559
前列腺癌免疫检查点抑制剂治疗:现在和未来的前景
1Department of Translational Research, Western University of Health Sciences, Pomona, CA 91762, USA.
Biomolecules
|June 26, 2025
概括
本综述涵盖前列腺癌治疗方法,重点关注晚期免疫检查点抑制剂 (ICI) 的挑战. 它探讨了转移性割耐性前列腺癌 (mCRPC) 的组合疗法和新的治疗前景.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 前列腺癌是一种普遍存在的恶性瘤,其特征是不受控制的细胞生长.
- 已经确立的手术,放射,激素和化疗等治疗方法面临的挑战是晚期疾病的治疗耐药性.
- 新兴的免疫检查点抑制剂 (ICI) 疗法显示出前景,但在转移性割抵抗性前列腺癌 (mCRPC) 中遇到耐药性和有限的疗效.
研究的目的:
- 审查前列腺癌背后的分子和细胞机制.
- 讨论目前免疫治疗的现状和局限性,特别是针对晚期前列腺癌的ICI.
- 探索组合疗法和新的治疗策略对mCRPC的潜力.
主要方法:
- 关于前列腺癌中的分子和细胞机制的文献综述.
- 免疫疗法方法的分析,包括免疫检查点抑制剂 (ICI).
- 检查临床试验和对mCRPC组合疗法的研究.
主要成果:
- 治疗耐药性是晚期前列腺癌常规疗法的一个重要问题.
- 在mCRPC中观察到有限的疗效和对ICI的耐药性.
- 目前正在进行的组合疗法的临床试验提供了潜在的进展.
结论:
- 了解分子机制对于开发有效的前列腺癌治疗至关重要.
- 克服mCRPC中的ICI耐药性需要进一步的研究和创新的治疗策略.
- 组合疗法和新药开发有望改善晚期前列腺癌的治疗结果.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.0K
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
711
相关概念视频
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Vaccines
520
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
520
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K